CAJ | 학술논문

目的：探讨罗格列酮治疗2型糖尿病的临床疗效及心血管安全性。方法选取2008年3月-2011年3月医院收治的2型糖尿病患者120例，随机分为2组，每组60例。治疗组60例给予马来酸罗格列酮4mg，每天1次，并联合精蛋白锌生物合成人胰岛素注射液预混30R 治疗；对照组60例给予精蛋白锌生物合成人胰岛素注射液预混30R 治疗，根据血糖要求调整个体化的胰岛素给药剂量。每3个月监测患者体质量、血压、血糖、糖化血红蛋白（HbA1c）、血脂、心电图及心脏彩超，监测期为2年，数据进行统计分析。结果治疗后，治疗组合并原发性高血压患者血压下降，与对照组差异显著（P <0.05）；治疗组未合并高血压患者下降不明显。治疗组治疗后空腹血糖（FBG）、餐后血糖（2hPG）、HbA1c、三酰甘油（TG）与治疗前比较明显下降（P <0.01），与对照组比较有显著差异。用药24个月中，监测心电图及心脏彩超均合格，治疗过程患者无明显不良反应。结论罗格列酮联合生物合成人胰岛素30R治疗2型糖尿病，能显著降低2型糖尿病并原发性高血压患者血压，降低患者 FBG、2hPG、HbA1c、三酰甘油（TG），其临床疗效同样确切，甚至更优，且心血管系统不良反应小，安全性好。
목적：탐토라격렬동치료2형당뇨병적림상료효급심혈관안전성。방법선취2008년3월-2011년3월의원수치적2형당뇨병환자120례，수궤분위2조，매조60례。치료조60례급여마래산라격렬동4mg，매천1차，병연합정단백자생물합성인이도소주사액예혼30R 치료；대조조60례급여정단백자생물합성인이도소주사액예혼30R 치료，근거혈당요구조정개체화적이도소급약제량。매3개월감측환자체질량、혈압、혈당、당화혈홍단백（HbA1c）、혈지、심전도급심장채초，감측기위2년，수거진행통계분석。결과치료후，치료조합병원발성고혈압환자혈압하강，여대조조차이현저（P <0.05）；치료조미합병고혈압환자하강불명현。치료조치료후공복혈당（FBG）、찬후혈당（2hPG）、HbA1c、삼선감유（TG）여치료전비교명현하강（P <0.01），여대조조비교유현저차이。용약24개월중，감측심전도급심장채초균합격，치료과정환자무명현불량반응。결론라격렬동연합생물합성인이도소30R치료2형당뇨병，능현저강저2형당뇨병병원발성고혈압환자혈압，강저환자 FBG、2hPG、HbA1c、삼선감유（TG），기림상료효동양학절，심지경우，차심혈관계통불량반응소，안전성호。
Objective Discusse the clinical efficacy and cardiovascular security of type 2 diabetes mellitus using Ros-iglitazone. Methods 120 patients with type 2 diabetes mellitus were chosen as samples from March,2008 to March,2011. 60 patients in treatment group were treated by 4mg qd rosiglitazone maleate together with protamine and zinc photosynthesis human insulin injection,which was premixed for 30R. On the other hand,60 patients in control group were treated by protamine and zinc photosynthesis human insulin injection only,which was premixed for 30R,and the individual drug dosage of insulin was adjusted according to glucose requirement. Results The SBP and DBP values of patients with type 2 diabetes mellitus and es-sential hypertension in treatment group was significantly different comparing with that in control group(P < 0. 05);The de-crease of patients without hypertension in treatment group was not significant. The FBG,2hPG and HbA1c of patients in treat-ment group decreased significantly comparing to that before treatment(P < 0. 01). It was significan difference comparing to control group. During the 24 months treatment period,the monitoring ECG and Echocardiography of patients was qualified,and the patients has no significant adverse reactions. Conclusions When the patients with type 2 diabetes mellitus was treated u-sing Rosiglitazone,the blood pressure of patients with essential hypertension can be decreased significantly,and the patients'FBG,2hPG,HbA1c and TG was decreased,the clinical efficacy was also reliable,and even better,there is little adverse reac-tions in cardiovascular system,and the security is high.